individuals. 3, 21, 37, 38, 41 Moreover, excessive secretion of GH can cause several complications including cardiovascular diseases, musculoskeletal deformity, and diabetes mellitus as well as several malignancies. Death, in many cases, is caused by cardiovascular or cerebrovascular events. Importantly, the normalization of GH levels alleviates symptoms and reduces mortality rates to the levels in the general population.
Growth hormone levels and age-matched IGF-I concentrations are also significant for monitoring progression of the disease or the response to the treatment. 19 Resection of the adenoma is often the first-line treatment. 10, 13 Indeed, in patients with intrasellar microadenomas, microsurgical removal of the tumor alone is sufficient for biochemical control because it normalizes the IGF-I in 75%-95% of patients. On the other hand, in macroadenomas, control rates decrease to 40%-68%. 21, 42 In some cases, somatostatin analogs and the GH receptor antagonist pegvisomant or radiotherapy can be considered as additional treatment options after resection of the tumor. 29, 42 Although transsphenoidal microsurgery has been considered to be the best surgical approach in the treatment of GH-secreting adenomas, in the last decade endoscopic treatment of sellar lesions proved to be an important option as well. 19, 22, 30, 39 The endoscopic approach has some obvious advantages, including improved surgical visualization, less nasal trauma, increased patient comfort, and potentially better results with respect to total tumor resection. 15, 17, 19 Important changes have been introduced to the cure criteria for acromegaly. A consensus statement in the year 2000 proposed that IGF-I levels within an age-and sexadjusted normal range and a GH nadir of < 1 μg/L or GH levels < 1 μg/L after administration of the oral glucose tolerance test (OGTT) are the criteria for cure. 17 However, with the advent of highly sensitive immunoassays it is now possible to measure < 1 μg/L, or perhaps < 0.4 μg/L for glucose-suppressed GH levels in healthy individuals. [15] [16] [17] Accordingly, a current consensus in 2010 redefined cure as IGF-I levels within an age-and sex-adjusted normal range and a GH nadir of < 1 μg/L or GH levels < 0.4 μg/L after OGTT. 18 Because we evaluated our patients after surgery, we considered the GH level during OGTT proposed in the 2010 consensus guideline as a criterion for disease control.
In this study, 214 patients with GH-secreting pituitary adenomas who underwent endoscopic transsphenoidal surgery are presented. For a comparison of our results with others in the literature, we analyzed our data according to both the consensus criteria stated in 2010 and the previous consensus criteria developed in 2000. We compared the data in the cases considered as cured according to current criteria with the cases considered as "cured" according to the critera in 2000 but "uncured" according to the current criteria.
Methods

Patient Population
This study used the medical records of 214 consecutive patients who were surgically treated by the senior author (M.B.) in the Hacettepe University Hospital Neurosurgery Department between January 2006 and April 2012. The study was performed under the authorization of the ethics committee of Hacettepe University, Faculty of Medicine, and all patients agreed with the proposed treatment after careful explanation of all options for the management of acromegaly. We used the following guidelines for inclusion: 1) clinical diagnosis compatible with acromegaly (clinical presentation of acromegaly); 2) GH > 1 μg/ml after a 75-g oral glucose load and subsequent measurements of GH and glucose every 30 minutes over 2 hours; 3) increased age-and sex-adjusted IGF levels; 4) presence of GH-secreting pituitary adenomas; 5) positive GH marker in immunohistochemical examination; and 6) surgery performed by the senior author. Preoperative diagnostic tests and workup were performed in collaboration with the neurosurgery, endocrinology, otorhinolaryngology, and radiology clinics.
Endocrine Assessment
All patients were tested for their fasting GH and IGF-I levels and anterior pituitary function. After a basal GH and IGF-I level measurement, all patients had an OGTT. All patients were also examined for visual field deficits.
Following the operation, 1-day, 1-week, 1-month, 3-month, and 6-month postoperative fasting plasma GH and IGF-I levels were measured. Afterward, GH and IGF-I levels were reanalyzed at every 6 months. Appropriate hormone replacement therapy was administered to patients with clinical and laboratory signs and symptoms of hypopituitarism. At the 3-month postoperative follow-up, patients were analyzed according to the cure criteria for acromegaly published in 2010. 18 Patients were defined as cured according to hormonal cure criteria (that is, IGF-I levels restored to normal values for age and sex, and the suppressed GH level below 0.4 μg/L according to the OGTT-GH suppression test), as well as surgical criteria that no residual tumor was visualized by the endoscope intraoperatively and that total removal of the tumor was confirmed by the MRI studies obtained after administration of contrast material both on the 1st postoperative day (senior surgeon's own clinical approach) and at the 3-month follow-up.
Because the OGTT-GH suppression test could not be applied to all patients at the 1-year follow-up, we assessed the cure at the 1-year visit according to random GH levels. Patients with IGF-I levels within an age-and sex-adjusted normal range, random GH levels < 1 μg/L, and pituitary MRI studies free of tumor were accepted as cured. It is important to note that in the patients accepted as cured following the 3-month follow-up, MRI studies and hormone levels of IGF-I and GH confirmed the cure on the 6-month and 1-year follow-up.
Laboratory Analysis
Venous blood was sampled after an overnight fast and centrifuged at 3000 rpm for 30 minutes at 4°C. Serum GH levels were measured by immunoradiometric assay (IRMA), using commercially available kits (human GH, IRMA CT; RADIM). The sensitivity of the assay was 0.04 ng/ml. The calibrator was adjusted against the WHO 80/505 international standard preparation (1 ng human GH = 2 μIU). Reference levels for GH in women and men were 0-16 ng/ml and 0-8 ng/ml, respectively. Serum IGF-I was measured by a solid-phase, enzyme-labeled chemiluminescent immunometric assay (Im mu lite IGF-I, Siemens Medical Solutions Diagnostics UK), using the IMMULITE 1000 System. Calibration was up to 1600 ng/ml (WHO National Institute for Biological Standards and Control 1st International Reference Reagent [NIBSC 1st IRR] 87/518). The within-run coefficients of variation were 3.1%, 4.3%, and 3.5% for low, medium, and high points of the standard curve, respectively. The total coefficients of variation were 6.1%, 6.9%, and 5.8% for low, medium, and high points of the standard curve, respectively.
Serum levels of thyroid-stimulating hormone, free thyroxine, adrenocorticotropic hormone, growth hormone, follicle-stimulating hormone, luteinizing hormone, estradiol, testosterone, and free testosterone were determined using commercial immunoassay kits.
Pituitary Imaging
Magnetic resonance imaging of the sellar region was performed before and after intravenous contrast administration. High-resolution paranasal sinus CT sections were taken and reconstructed in 3D fashion (axial, sagittal, and coronal plane). Patients underwent MRI sequences on the 1st postoperative day, and then at the 3-month and 1-year follow-up visits.
Magnetic resonance imaging was performed at 1.5 T, in sagittal and coronal planes with 2.5-mm slice thickness, without an interslice gap. The T1-weighted spin echo images were acquired with a TR of 500 msec and a TE of 15 msec, both before and after administration of 5 ml of Gd contrast. Based on MRI findings, pituitary tumors of < 10 mm in diameter were defined as microadenomas whereas tumors ≥ 10 mm in diameter were defined as macroadenomas. Suprasellar and parasellar tumor extensions, which are usually considered important in the successful resection of the tumor, were evaluated according to the Hardy classification.
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Surgical Technique
All patients were treated using the endoscopic endonasal transsphenoidal approach by a team consisting of an otolaryngologist, the senior neurosurgeon, and an assistant neurosurgeon as described in our previous studies. [4] [5] [6] Because patients with acromegaly differ from other pituitary adenoma cases with respect to increased osteoblastic activity and vascular tortuosity, 12,43 a more extended approach was performed for these particular cases. In the nasosphenoidal stage, sella was exposed from one carotid protuberance to the other, and craniocaudally from the planum sphenoidale to the clivus. It is important at this stage that the intrasphenoidal septal anatomy, which, like fingerprints, is unique for every person, is clearly visualized preoperatively and that its relation and proximity to the carotid and optic protuberance is defined. Accordingly, patients underwent preoperative 3D paranasal CT scanning, and these anatomical characteristics were evaluated neuroradiologically before the operation.
Because tumors infiltrating or invading the cavernous sinus cause important changes in the course of the ICA, it is important to identify the course of this vessel 4, 11, 43 in the cavernous sinus preoperatively for a successful operation without any complications. The course of the ICA should therefore be identified with T2-weighted and T1-weighted 3D MRI obtained after addition of Gd. Moreover, multidetector CT angiography is necessary for the diagnosis of carotid dehiscense (reported in the literature as 1% in cadaver studies and identified in only 1 of our 214 cases), and 3D CT angiography should be used to identify aneurysms that might develop in patients who had previously undergone an operation for cavernous sinus invasion.
In this part of the surgery, the sellar floor is removed from one carotid protuberance to the other. The bone over the cavernous sinus is removed when indicated, and then the dural opening is made from the medial cavernous sinus walls and from the intercavernous sinus to the clivus. The 3-hand binostril bimanual technique is used in the removal of the tumor. Finally the tumor is excised together with a small piece (approximately 1-2 mm) of normal pituitary tissue.
Statistical Analysis
The Statistical Package for Social Sciences (SPSS version 13.0) was used for data analysis. Baseline and postoperative values were presented as the mean ± SD for continuous variables; rates and proportions were calculated for categorical data. All quantitative variables showed normal distribution (normality of distribution was assessed using the Kolmogorov-Smirnov test). Differences between groups in univariate analysis were detected using the unpaired Student t-test for continuous variables and the v2-test and Fisher exact test (when appropriate) for categorical variables. The statistical significance of the differences between the measurements before and after surgery was evaluated using paired t-test or Wilcoxon signed-rank test, when appropriate. Degrees of association between continuous variables were calculated using the Pearson "r" correlation coefficient. Linear regression analysis was used to determine the most important predictors affecting the cure status.
The optimal cut-off points of variables to determine the cure were evaluated by receiver operating characteristic analysis, and the value with the highest sum of sensitivity and specificity was taken as the cut-off value. Sensitivity (q) and specificity (p) are both functions of a certain cut-off point, with maximum {q(c) + p(c) − 1} occurring at the optimal cut-off point (c). The point that achieves this maximum is referred to as the optimal cut-off point (c) because it is the one that optimizes the biomarker's differentiating ability when equal weight is given to sensitivity and specificity. The area under the curve (AUC) and 95% CIs were also calculated.
A p value < 0.05 was considered statistically significant.
Results
Patient Characteristics
A total of 214 patients with GH-secreting pituitary adenoma were treated in the Department of Neurosurgery at Hacettepe University between January 2006 and April 2012. There were 108 (50.5%) female and 106 (49.5%) male patients. The mean age was 41.9 ± 12 years (minimum 17, maximum 75 years). The study included 163 macroadenomas (76.2%) and 51 microadenomas (23.8%). Characteristics of the study population are summarized in Table 1 . The majority of these patients had signs and symptoms of acromegaly. Besides these individuals, 4 patients complained also of visual defects and 3 patients were admitted to our clinic for ophthalmoplegia. Preoperative MRI studies obtained after administration of contrast material revealed cavernous sinus-invading tumors in 54 patients ( Table 2 , Fig. 1 ).
Immunohistochemical examinations revealed GH-secreting adenomas in all patients. The patients considered cured at the 3-month follow-up had no relapse in the ensuing follow-up period. The average follow-up period, from the resection to the latest laboratory testing, was 33.3 ± 16.6 months (range 6-90 months).
The total of 237 surgeries performed in this series are grouped into 2 categories: 1) primary surgeries-this group includes patients in whom the first and only surgery was performed by the senior surgeon (169 surgeries); and 2) repeated surgeries-this group includes the patients in whom the first surgery was performed in another clinic (45 surgeries) as well as those whose first operation was performed by the senior surgeon (16 surgeries). Of the 45 repeat surgery cases, 6 patients underwent 2 operations by the senior surgeon, and 1 of these 6 underwent an additional surgery. Twenty-one patients (9.8%) with macroadenomas also had elevated prolactin levels (> 25 ng/ml) at the preoperative evaluation. In 18 of these patients the prolactin levels were normalized after surgery; in the other 3 the prolactin levels were stabilized at the 6-month followup study without using dopamine agonists. A total of 7 patients had tumor apoplexia, and 17 patients (7.9%) had pituitary dysfunction preoperatively. Three of the 7 apoplexia cases and 2 patients with Hardy Grade E adenoma had panhypopituitarism. Twelve patients had partial hypopituitarism, 7 patients (3 female, 4 male) had hypogonadism, 3 had hypothyroidism, and 2 had hypocortisolemia.
Evaluation of the Parameters Associated With Disease Cure
Cure was achieved in 134 (62.6%) of 214 patients. Cure was achieved in 109 (64.5%) of the 169 primary surgery cases (cases in which only 1 operation was done, by the senior surgeon) and in 25 (41%) of the 61 cases in which a repeat operation was performed (p < 0.001). The microadenoma/macroadenoma ratio was similar in the cases with primary and repeat operations (39/129 in primary and 12/34 in repeat operations, p = 0.892). The cured and uncured cases showed no statistically significant difference in terms of sex either (p = 0.677). The cure rate was found to be similar in microadenomas and macroadenomas (62.8% and 62.6%, respectively; p = 0.809). In the cured group, basal IGF-I levels and basal GH levels were significantly lower compared with the uncured group (Table 3) .
In the postoperative period, beginning with the Day 1 follow-up study, postoperative GH and IGF-I levels were found to be consistently lower in the cured cases (p < 0.001). For clarity, we analyzed the postoperative IGF-I levels by grouping the patients according to decrease in IGF-I levels as follows: Group I, 0%; Group II, 1%-24.9%; Group III, 25%-49.9%; and Group IV, ≥ 50%. The number of patients in Group II at the postoperative Day 1 followup was high. Similarly, the number of Group III patients at the postoperative Week 1 follow-up was also high, but the number of Group IV patients was significantly higher at the postoperative 1-month follow-up visit (Fig. 2) . On the other hand, the cured cases had the lowest IGF-I levels throughout the entire follow-up period (Table 4) . In predicting the cure, a 14.4% decrease in the Week 1 IGF-I levels was 66.7% sensitive and 57.9% specific for cure (AUC 0.638; 95% CI 0.484-0.793). Similarly, a 51.1% decrease in the 1-month IGF-I levels was found to be 74.4% sensitive and 73.7% specific (AUC 0.823, 95% CI 0.715-0.932).
The cut-off GH levels for predicting the cure on the 1st postoperative day, in the 1st week, and in the 1st month were 2.33 μg/L (65.2% sensitivity and 77.3% specificity, AUC 0.772, 95% CI 0.654-0.890), 2.05 μg/L (87.0% sensitivity and 79.5% specificity, AUC 0.817, 95% CI 0.709-0.924), and 2.25 μg/L (78.3% sensitivity and 75.0% specificity, AUC 0.805, 95% CI 0.700-0.910), respectively (Fig. 3) . In regression analysis, 3-month GH levels were considered to be independent criteria for cure (Table 5) .
Evaluation of the Number of Cases Necessary for the
In all operations the cut-off point for the number of surgeries needed for a practitioner to increase cure rates was 108, with 62.3% sensitivity and 50.6% specificity (AUC 0.627, 95% CI 0.552-0.702). The cure rate was 45.8% for the patients who underwent operations before this cut-off point and 79.4% for the patients who were surgically treated after the cut-off point (p = 0.037) (Fig. 4) .
In the patients in whom the first surgery was endoscopic endonasal transsphenoidal surgery performed by the senior surgeon, the cut-off point at which surgical experience increased the practitioner's cure rates was 57 operations, with 72.6% sensitivity and 46.4% specificity (AUC 0.655, 95% CI 0.571-0.738). The cure rate for the patients who were surgically treated before this cut-off point was 58.5% and the cure rate for the patients treated after the cut-off point was 72.6% (p = 0.025) (Fig. 4) .
For ease in comparing our results with those of the previous reports, we reanalyzed our data according to the 2000 consensus criteria and obtained a remission rate of 75.2% in our series (Table 6 ). To explain this 12% difference in cure rate, we compared the data in these "uncured" patients who were defined as cured according to the 2000 criteria with the ones who were considered cured according to 2010 consensus criteria. Twenty-eight patients were found to be in remission with the previous criteria, but not in remission according to the current consensus. Random GH levels were found to be < 1 μg/L in 9 of these patients (32.1%), 1-2 μg/L in 12 patients (42.9%), and > 2 μg/L in 7 patients (25%). When these patients were compared with the cured cases according to the current criteria, IGF-I and GH levels at the 1-year follow-up were found to be similar.
Surgical Complications
In our study, surgery-related complications such as epistaxis (1 of 237 surgeries), postoperative CSF leakage (5 of 237), sinusitis (1 of 237), and meningitis (1 of 237) were detected in 17 operations. Endocrinological complications were seen in 9 operations. Hypocortisolemia was detected in 5 patients; 3 of them had thyroid deficiency and 2 had hypogonadism with adrenal insufficiency. One patient with invasive adenoma experienced panhypopituitarism including hypogonadism, hypoadrenalism, and hypothyroidism, which lasted for 1 year in the postoperative period. Posterior hypophysial insufficiency was detected in 3 patients; 2 of them had permanent diabetes insipidus (2 of 237), and 1 had syndrome of inappropriate antidiuretic hormone (1 of 237). Intraoperative CSF leaks were observed in 29 (12.2%) of 237 cases, but only 1 of these had to undergo a repeat operation for postoperative CSF leaks. There were no surgery-related deaths.
Discussion
The main aim in the surgical treatment of acromegaly is the total resection of the tumor in the pituitary gland, if possible, and prevention of its recurrence. 27, 34, 39 Therapy for acromegaly aims to manage the tumor growth as well as GH hypersecretion and IGF-I levels. The long-term objective, hence, is to reduce the morbidity and mortality rates to comparatively normal rates in the general population. 7, 41 The definition of biochemical remission of acromegaly has changed noticeably over the past 2 decades. Throughout the 1980s, postoperative GH levels < 5 μg/ ml were considered as criteria of biochemical remission of disease, allowing a surgical success in more than 75% of patients in some large series.
1 However; mortality rates remained high without normalized GH and IGF-I levels. 3 Therefore, more stringent criteria to define the biochemical remission of acromegaly have been proposed in recent years. Using a mean GH < 2 μg/ml during OGTT and normal IGF-I levels, biochemical remission of acromegaly has been reported in 55%-70% of patients. 15 In 2000, the Acromegaly Treatment Workshop presented the international consensus criteria for the treatment of acromegaly. According to this consensus, the GH had to be suppressed during OGTT to < 1 μg/L and IGF-I had to be within normal limits for acromegaly to be considered in complete remission. 17, 26, 33 However, these values were questioned in 2005 by a consensus workshop, which stated that GH nadir values should more closely approximate those of healthy individuals, and thus GH after OGTT should be < 0.4 μg/L. 32 In 2010 a recent consensus was reported, which described "cure" as random GH < 1 μg/L and IGF-I levels within an age-and sex-adjusted normal range, or nadir GH levels < 0.4 μg/L with OGTT.
There have been many reports on postoperative remission rates of GH-secreting pituitary adenomas treated with both microsurgical and endoscopic procedures. Recent microsurgical studies reported remission rates of 55%-72.9% using 2000 consensus criteria 26, 28, 35, 36 (Table  7) . However, Albarel et al. 2 analyzed their data using the most recent consensus, and reported a 49.5% remission rate.
Reports on endoscopically assisted resection of GHsecreting pituitary adenomas demonstrated disease control in 58%-75% [7] [8] [9] 14, 19, 25 of the cases according to the less stringent 2000 criteria. Although they found a relatively higher percentage of cure, the number of cases and the follow-up period were lower than ours.
Because most of the data in the literature about the remission rates in acromegaly were accrued according to previous consensus criteria, it was not possible to compare them directly to our remission rate. Therefore, we reanalyzed our data using the 2000 criteria and obtained a remission rate of 75.2% in our series, which is higher than the rate of 62.6% achieved using the 2010 criteria. This finding raises the question of whether these remaining "uncured" patients (approximately 12%) would ever meet 2010 consensus criteria. Therefore, we compared the data in these patients to the data in patients who were cured according to 2010 criteria. We found out that the GH and IGF-I levels of these "uncured" cases decreased to the hormone levels of the cured cases at the 1-year follow-up.
Even in 32% of these cases, 1-year GH levels were found to be between 0.4 and 1 μg/L. This result indicates that although the 2010 consensus criteria have strict guidelines, many patients who fail to attain a cure according to the 2010 consensus criteria may however fulfill these criteria in a longer follow-up period. Additionally, for those who have GH levels < 1 μg/L but fail to fulfill the most recent criteria for cure, additional medical therapy should be reconsidered if MRI studies show no tumor. Currently, there are only 3 reported endoscopic studies that have been conducted using the 2010 criteria for remission. These studies have reported 46%, 21 70%, 23 and 50.9% 40 cure rates. Using the same consensus criteria as these reports, our study of 214 acromegaly cases is a unique GH-secreting adenoma series because it has the highest number of cases with relatively higher cure rates. In one of these previously published series 23 it was claimed that morning GH levels < 2.5 μg/ml provided the best prediction of remission, and that preoperative basal IGF-I and GH levels were also found to be predictive of remission. However, their 2-month follow-up time was rather short.
In our report, we began to assess GH and IGF-I levels as early as the 1st day, followed by the 1-week and 1-month follow-up visits, and continued thereafter. We also reviewed the data for a longer mean follow-up of 33.6 months. We found that a 51.1% decrease in postoperative 1-month IGF-I levels was predictive of cure, with 74.4% sensitivity and 73.7% specificity. Moreover, random GH levels < 2.33 μg/L detected after the 1st postoperative day follow-up were found to be predictive of cure. Basal GH and basal IGF-I levels were found to have no effect on achieving cure, either. Neither age and sex difference nor the primary or secondary surgeries had any impact on cure (Table 5) . We observed that 3-month GH levels were statistically significant to achieve cure. Shin et al. 40 also claimed that 3-month hormone levels are valuable in predicting the cure, in their report with a similar follow-up period but with a smaller number of patients.
It is argued that neuroendoscopy and the endoscopically guided transsphenoidal pituitary surgery have better results in tumor resection as a result of better visualization of the sella, less nasal dissection, and improvement in the resection of suprasellar and parasellar components of the adenoma. 14, 19, 43 This advantage of endoscopy would be more appreciated in macroadenomas and in adenomas invading cavernous sinuses. Recent studies stated that 23, 40 Knosp grades of 3 and 4 and Hardy Grades C, D, and E are predictive values in achieving cure. One of these reports had 82% macroadenomas with 46.9% Hardy Grades C, D, and E cases, and achieved 46.7% remission for macroadenomas and 34.8% remission for Hardy Grade C, D, and E cases. 40 We had 54 adenoma cases with cavernous sinus invasion (Hardy Grade E) and managed to cure 22 (40.7%) of these cases (Table 2) , which is considerably higher than reported in the literature. However, in our series adenoma size and Hardy grades were found to have no effect on achieving cure. We suggest that the high cure rate achieved in the treatment of the cavernous sinus-invading adenomas is due to the extended approach used in the sphenoidal stage. We are able to identify the normal pituitary tissue and the possible residual tumoral tissue on the cavernous sinus wall because the camera and the light of the endoscope allow a closer and clearer view of the surgical field. Moreover, we can check the intercavernous or the suprasellar field after the removal of the tumor for any remaining tumoral pieces and potential defects of the diaphragm, and proceed accordingly. In our study, the extended approach significantly increased the maneuverability of the instruments and helped us to see the wall of the cavernous sinus better. 24, 30 Moreover, with complications in only 17 cases, we had a significantly lower complication rate when compared with other endoscopic series presented in the literature. Only 3% of our cases had anterior pituitary dysfunction and 1% had posterior pituitary dysfunction.
Many theoretical benefits of the endoscopic approaches notwithstanding, the most important factor in achieving good results in the endoscopic approach is evidently the experience of the surgeon. Hence, although the endoscopic access to the sellar region is a relatively new technique, performing more surgeries with both hands using endoscopic guidance will certainly contribute to surgeon competence and better use of this technique. 5, 6 Thus, with this report we determined a cut-off value of the number of surgeries needed to achieve better cure rates. We observed a significant increase in the cure rate after the 57th primary surgically treated case and the 108th of all surgically treated cases. The cure rates for the patients who underwent surgery before this cut-off point were 58.5% for the primary operations and 45.8% overall, whereas these figures rose to 72.6% and 79.4%, respectively, for the patients operated after the cut-off point. According to these data, especially for the primary operations, in the remaining 112 cases in which the surgeon operated after the cut-off value, the cure rate was even higher (72.6%). Although the cut-off value for the number of surgeries may vary for each surgeon, 50 surgeries for the primary and 100 surgeries for the overall number of operations seem to be the cut-off point for the surgeons to achieve sufficient surgical experience for higher cure rates.
Conclusions
With this report, we introduce the highest number of GH adenomas with relatively high cure rates in the literature according to the most recent consensus criteria. We emphasize the importance of a > 50% decrease in postoperative 1-month IGF-I levels and random GH levels < 2.33 μg/L detected after the 1-day postoperative follow-up scan was obtained in predicting the cure in patients with acromegaly. One of the most important highlights of our study is that we analyzed our data with both of the consensus criteria used in the literature. We concluded that although the 2010 consensus criteria imply strict guidelines, many patients who will fail to be defined as cured may fulfill these criteria in a longer follow-up period. For those who have GH levels < 1 μg/L and MRI studies free of tumor at the 3-month follow-up visit but fail to fulfill the current cure criteria for acromegaly, additional therapy need not be rushed; these patients will be in remission at the 1-year follow-up. It must be noted that surgeon experience is of great significance in achieving high cure rates. Approximately 50 operations for the primary and 100 operations for the overall acromegaly cases, mainly with macroadenomas, seem to be reasonable "thresholds" for the surgeon to achieve higher rates of cure.
